


**Product Name** : PAT-1102  
**Cat. No.** : PC-24698  
**CAS No.** : 2641930-61-0  
**Molecular Formula** : C<sub>21</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 413.91  
**Target** : HDAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

PAT-1102 (FND-20123) is a novel, potent, orally available HDAC inhibitor with IC<sub>50</sub> of 3 nM in cell-free HDAC enzymatic assays, also inhibits Plasmodium HDAC with IC<sub>50</sub> of 31 nM.

PAT-1102 (FND-20123) inhibits *P. falciparum* in asexual blood-stage assay with IC<sub>50</sub> of 42 nM.

PAT-1102 (FND-20123) shows activities against various HDAC isoforms, HDAC1, 2, 3, 6 and 8.

PAT-1102 (FND-20123) induces caspase-3 activation in HT-29 cells with EC<sub>50</sub> of 1.36 μM.

PAT-1102 (FND-20123) exhibits growth-inhibitory properties against a panel of cancer cell lines.

PAT-1102 (FND-20123) (50 mg/kg, p.o.) induces significant dose-dependent tumor growth inhibition in subcutaneous xenograft model established with HCT-116 colorectal carcinoma cells in SCID mice.

PAT-1102 (FND-20123) exhibits vivo efficacy in a mouse model for Plasmodium falciparum infection.

## References

Hiriyani J, et al. Anticancer Res. 2015 Jan;35(1):229-37.

Vijay Potluri, et al. Malar J. 2020 Oct 12;19(1):365.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com